<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450708</url>
  </required_header>
  <id_info>
    <org_study_id>15-059</org_study_id>
    <nct_id>NCT02450708</nct_id>
  </id_info>
  <brief_title>Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes</brief_title>
  <official_title>Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study tests whether adding certain genetic factors to the process of picking a stem cell
      donor can decrease the chances that the patient's leukemia will come back after bone marrow
      transplantation. Stem cell donors are &quot;matched&quot; based on genes called human leukocyte
      antigens (HLA).

      Currently, donors are selected largely on the basis of HLA gene typing alone. There is
      published data to show that donors with specific other genes called killer
      immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia
      return after a transplant. In this study, the best HLA matched donors will be tested for the
      KIR genes. If there is more than 1 donor available, a recommendation will be provided to
      study doctors as to which donors have potentially favorable KIR genes. The study doctors may
      or may not choose to use this donor for transplant or not based on his/her own judgment.
      Transplant care will not change otherwise as a result of this study.

      This study is being done to demonstrate that AML patients who have donors with specific KIR
      and HLA genes will have a better outcome following transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Demonstration of evidence of leukemia (&gt;5% blasts in the bone marrow, peripheral blood blasts, or development of extramedullary disease) after initial achievement of either a CR or CRi.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival (OS). The time from study enrollment until death from any cause.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>For patients with 1 HLA-compatible donor for URD HCT</arm_group_label>
    <description>For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>For patients with &gt;1 HLA-compatible donor for URD HCT</arm_group_label>
    <description>For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>KIR genotyping</intervention_name>
    <arm_group_label>For patients with &gt;1 HLA-compatible donor for URD HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>HLA genotyping</intervention_name>
    <arm_group_label>For patients with 1 HLA-compatible donor for URD HCT</arm_group_label>
    <arm_group_label>For patients with &gt;1 HLA-compatible donor for URD HCT</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The trial will recruit potential transplant eligible participants with AML in clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        RECIPIENT

          -  Persons of all ages are eligible for this study.

          -  Patient must have diagnosis of acute myelogenous leukemia (AML) at MSK or a
             collaborating treating institution. Patients with de novo AML or AML with preceding
             myelodysplastic syndrome (MDS) are eligible.

          -  Patient must be a potential candidate for an unrelated transplantation procedure at
             the time of enrollment even though patient may not be eligible for transplantation in
             the future due to relapse or presence of co-morbidity(ies).

          -  An unrelated donor does not need to be identified at the time of enrollment. If an
             HLA-compatible unrelated donor is not identified for the patient, the patient will be
             removed from the study.

        Exclusion Criteria:

          -  Recipients with an available sibling donor matched at HLA-A, HLA-C, and HLA-DRB1
             (excluding identical twin siblings).

          -  Patients for whom post-transplant treatment is planned are not excluded from
             enrollment.

          -  Patients with prior allogeneic hematopoietic cell transplantation for AML. Note:
             Patients who have undergone prior hematopoietic cell transplantation for a diagnosis
             other than AML are still eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Hsu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharine Hsu, MD, PhD</last_name>
    <phone>646-888-2667</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Shaffer, MD</last_name>
    <phone>212-639-2212</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Anasetti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claudio Anasetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Cutler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Litzow, MD</last_name>
      <email>litzow.mark@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Rowley, MD</last_name>
      <phone>551-996-8297</phone>
    </contact>
    <investigator>
      <last_name>Scott Rowley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Hsu, MD, PhD</last_name>
      <phone>646-888-2667</phone>
    </contact>
    <contact_backup>
      <last_name>Brian Schaffer, MD</last_name>
      <phone>212-639-2212</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rizzieri, MD</last_name>
      <phone>919-668-1040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumithira Vasu, MBBS</last_name>
      <phone>614-293-3196</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Agura, MD</last_name>
      <phone>214-820-1800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Pidala, MD</last_name>
      <phone>813-745-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Effie Petersdorf, MD</last_name>
      <phone>206-667-5244</phone>
    </contact>
    <investigator>
      <last_name>Effie Petersdorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Cell Donors</keyword>
  <keyword>KIR and HLA Genotypes</keyword>
  <keyword>15-059</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

